EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms

Justin Halim, Andrew P Keane, Jeannete Bouzo, Tope Aderibigbe, Jessica A Chicola, Katie T Nolan, Keertana Jonnalagadda, Jason X Tran, Valerie J Carabetta iD

Journal of Antimicrobial Chemotherapy · 03.10.2025 · 80 (10) · 2814-2824

DOI: 10.1093/jac/dkaf306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 20.08.2025. Verfasst von Justin Halim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Anti-Bacterial Agents, Cephalosporins, Drug Synergism. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acinetobacter baumannii is a nosocomial pathogen known for rapidly developing resistance to nearly all antibiotics, including last-line agents. Cefiderocol, a novel siderophore cephalosporin, has shown in vitro activity against A. baumannii and is now used clinically, but resistance is emerging. Data on cefiderocol-based antibiotic combinations are limited.

Objectives

To evaluate the in vitro activity of cefiderocol alone and in combination with other antibiotics against XDR and PDR A. baumannii clinical isolates, and to explore resistance mechanisms underlying cefiderocol synergy.

Methods

We tested 21 XDR/PDR clinical isolates and one NDM-1-producing strain using broth microdilution and checkerboard assays with cefiderocol and 17 antibiotics, including ceftazidime/avibactam, sulbactam/durlobactam, and amikacin. Synergy was determined through checkerboard assays and calculating fractional inhibitory concentration indices (FICI). WGS was used to identify resistance genes in selected strains.

Results

Cefiderocol alone was active against 66.7% of strains and demonstrated synergy with ceftazidime/avibactam and sulbactam/durlobactam in 100% and 95.2% of strains, respectively, and with amikacin, doxycycline and sulbactam in over half of strains. Cefiderocol-based combinations also reduced cefiderocol MICs against an NDM-1-producing strain. WGS revealed β-lactamases and resistance determinants among both susceptible and resistant isolates.

Conclusions

Several cefiderocol-containing combinations show strong in vitro synergy against XDR and PDR A. baumannii. These combinations, especially cefiderocol-ceftazidime/avibactam and cefiderocol–sulbactam/durlobactam, may enhance treatment of highly resistant A. baumannii strains and warrant further clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiAnti-Bacterial AgentsCephalosporinsDrug SynergismDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsAcinetobacter InfectionsCefiderocolDrug CombinationsCeftazidimeAzabicyclo Compoundsbeta-Lactamases

Substanzen

Anti-Bacterial AgentsCephalosporinsCefiderocolDrug CombinationsCeftazidimeAzabicyclo Compoundsbeta-Lactamasesavibactam, ceftazidime drug combination

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ 08103, USA.
  • Rowan-Virtua School of Osteopathic Medicine, Stratford, NJ 08084, USA.
  • Department of Chemistry and Biochemistry, Rowan University, Glassboro, NJ 08028, USA.

ORCID-Profile: Valerie J Carabetta

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • National Institute of General Medical Sciences
  • National Institutes of Health

Zitieren

APA

Halim, J., Keane, A. P., Bouzo, J., Aderibigbe, T., Chicola, J. A., Nolan, K. T., Jonnalagadda, K., Tran, J. X., & Carabetta, V. J. (2025). Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms. Journal of Antimicrobial Chemotherapy, 80(10), 2814-2824. https://doi.org/10.1093/jac/dkaf306

Vancouver

Halim J, Keane AP, Bouzo J, Aderibigbe T, Chicola JA, Nolan KT, et al. Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms. Journal of Antimicrobial Chemotherapy. 2025;80(10):2814-2824. doi:10.1093/jac/dkaf306

BibTeX
@article{Halim2025,
  author = {Halim, Justin and Keane, Andrew P and Bouzo, Jeannete and Aderibigbe, Tope and Chicola, Jessica A and Nolan, Katie T and Jonnalagadda, Keertana and Tran, Jason X and Carabetta, Valerie J},
  title = {Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  volume = {80},
  number = {10},
  pages = {2814--2824},
  doi = {10.1093/jac/dkaf306}
}
Kostenlos starten →